Motor response to apomorphine and levodopa in asymmetric Parkinson's disease

Kempster, P A; Lees, A J
November 1994
Journal of Neurology, Neurosurgery & Psychiatry;Nov1994, Vol. 57 Issue 11, p1444
Academic Journal
No abstract available.


Related Articles

  • Subcutaneous apomorphine in Parkinson's disease. Chaudhuri, K Ray; Clough, C. // BMJ: British Medical Journal (International Edition);02/28/98, Vol. 316 Issue 7132, p641 

    Discusses the effectivity of continuous subcutaneous infusion of apomorphine in overcoming refractory on-off oscillations in Parkinson's disease. Motor response to apomorphine; Counselling of patients and liaison with the general practitioner; Benefits of apomorphine; Reluctance of neurologists...

  • Subcutaneous Apomorphine. Deleu, Dirk; Hanssens, Yolande; Northway, Margaret G. // Drugs & Aging;2004, Vol. 21 Issue 11, p687 

    Apomorphine, a short-acting dopamine D1 and D2 receptor agonist, was the first dopamine receptor agonist used to treat Parkinson's disease. Subcutaneous apomorphine is currently used for the management of sudden, unexpected and refractory levodopa-induced 'off' states in fluctuating Parkinson's...

  • Treatment of Parkinson's disease in the advanced stage. Ossig, C.; Reichmann, H. // Journal of Neural Transmission;Apr2013, Vol. 120 Issue 4, p523 

    Levodopa/Carbidopa, respectively, Levodopa/Benserazide is the most effective treatment for Parkinson's disease and during the progress of the disease, patients will inevitably need to be treated with it. Nonetheless, after a certain time period most of the patients experience side effects....

  • Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Nyholm, Dag // Clinical Pharmacokinetics;2006, Vol. 45 Issue 2, p109 

    Pharmacotherapy for Parkinson’s disease is focused on dopaminergic drugs, mainly the dopamine precursor levodopa and dopamine receptor agonists. The elimination half-life (t½) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more...

  • Advanced treatment needed for some.  // New Zealand Doctor;4/11/2012, p41 

    The article discusses the treatments for advanced Parkinson's Disease (PD) patients. It cites the two invasive forms of medical treatment for intractable motor complications, namely, apomorphine and levodopa gel (Duodopa) through percutaneous jejunostomy. The surgical therapies for PD include...

  • Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Neef, C.; van Laar, T. // Clinical Pharmacokinetics;1999, Vol. 37 Issue 3, p257 

    In the treatment of patients with Parkinson's disease, apomorphine has an established place as a back-up therapy if other antiparkinsonian drugs, such as levodopa and oral dopamine agonists, have not controlled the existing response fluctuations. Apomorphine is a synthetic derivative of...

  • Apomorphine/levodopa.  // Reactions Weekly;9/19/2009, Issue 1270, p8 

    The article describes a case of psychiatric disorders induced by treatment with levodopa and apomorphine. The male patient received apomorphine and levodopa to treat his early onset Parkinson's disease. Some of the psychiatric disorders developed by the man include paraphilia and abnormal...

  • Deep-Brain Stimulation for Parkinson's Disease. Lieb, Klaus; Schlaepfer, Thomas E. // New England Journal of Medicine;11/23/2006, Vol. 355 Issue 21, p2256 

    A letter to the editor is presented in response to the use of deep-brain stimulation for treating levodopa-related motor complications of advanced Parkinson's disease.

  • Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Stocchi, F.; Vacca, L.; De Pandis, M. F.; Barbato, L.; Valente, M.; Ruggieri, S. // Neurological Sciences;Feb2001, Vol. 22 Issue 1, p93 

    Fluctuations in motor disability and dyskinesias are the major problem in the long-term treatment of Parkinson's disease (PD). Many authors and ourselves have shown that by giving patients a continuous infusion of levodopa it is possible to control motor fluctuations. Levodopa can be...

  • Delayed early morning turn "ON" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered. Chciná, P.; Kuntsmann, C.; Reyes-Parada, M.; Sáez-Briones, P. // Journal of Neurology, Neurosurgery & Psychiatry;Dec2004, Vol. 75 Issue 12, p1782 

    Presents a letter to the editor on response to a single dose of levodopa in advanced Parkinson's disease.


Read the Article


Sign out of this library

Other Topics